U.S. Stock Market Midday Update

Vor BioPharma rose 14.79%, with increased trading volume. Based on recent important news:

1. On July 9, Zhou Haibing, Deputy Director of the National Development and Reform Commission, stated at a press conference that insurance institutions are accelerating their layout in the elderly care industry, launching products such as "elderly care community + insurance," which has driven related company stock prices up.

2. On July 8, Silchester International Investors LLP reduced its holdings in Hysan Development by 835,000 shares, leading to a decline in market confidence in related stocks.

3. On July 7, Accenture's public shareholding ratio was 20%, raising market concerns about the company's governance structure.

Stocks with High Trading Volume in the Industry

ProKidney rose 75.07%, with increased trading volume. Based on recent important news:

1. On July 8, ProKidney announced positive results from its REGEN-007 trial, showing that Rilparencel significantly improved the eGFR slope in chronic kidney disease patients, driving the stock price up by 75%.

2. On July 8, the company confirmed there were no serious adverse events, enhancing market confidence in its safety.

3. On July 8, trading volume surged to 39.8 million shares, far exceeding the average level, reflecting the market's strong reaction to the trial results.

Calidi Biotherapeutics rose 176.72%, with a trading volume of $200 million. Based on recent key news:

1. On July 8, Calidi Biotherapeutics published an editorial on NetworkNewsWire, increasing market attention towards it, resulting in a significant stock price increase of 176.72%.

2. On July 8, Jefferies raised the target price for Blackstone Group, indicating increased market confidence in the biotechnology industry, indirectly boosting Calidi's stock price.

3. On July 9, Furuno Electric reported a significant profit increase, indicating overall improvement in the electronics industry, boosting market sentiment.

AbbVie fell 0.21%, with increased trading volume. Based on recent important news:

1. On July 9, analysts noted that AbbVie was not on the recommended list, despite a rating of moderate buy, leading to pressure on the stock price.

2. On July 8, advancements in CAR-T cell therapy in the field of autoimmune diseases may affect AbbVie's market competitiveness.

3. On July 7, increased volatility in the innovative drug industry affected investor confidence.

Stocks with High Market Capitalization in the Industry

AbbVie fell 0.21%, with increased trading volume. Based on recent important news:

1. On July 9, analysts noted that AbbVie was not on the recommended list, leading to a decline in investor confidence and a 0.21% drop in stock price

2. On July 8th, the innovative drug industry experienced increased volatility, with a low allocation ratio by institutions affecting market sentiment.

3. On July 7th, the progress of CAR-T therapy in the field of autoimmune diseases failed to boost Abbvie's stock price